SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Welcome to the POTP board, the DPP-IV company
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: pgo-neil1/12/2007 8:45:55 AM
  Read Replies (1) of 90
 
POTP to continue phase 2 Pancreatic trials. About 10% response rate [N=21, good PFS and good [maybe great] six month survival. Target is to have N=60 by mid-07.

Their announced continuation of phase IIIs for NSCLC last month puts them on track for a license application in early 2008 for NSCLC. These other phase 2's should prove useful in off-label after it reaches market.

Only 2 things bother me about this stock:
1. Yahoo shows $15M cash at Sept 2006 and burn rate of $29M. They need more money soon. That is the reason for the free fall to 80 cents.

2. Their chief Development officer has the last name U'Pritchard. How many unrelated folks with that name can there be in the biotech universe... Thinking David of DDDP.

From the companies website: phx.corporate-ir.net

Of the 21 evaluable patients who entered the study at least six months ago, ten (48%) have survived more than six months. In addition, 31 patients are currently evaluable for tumor response. To date, three patients (9.7%) have demonstrated a clinical response to treatment, including one complete response and two partial responses. One patient with metastatic disease to the liver experienced a complete response to treatment--defined as the complete disappearance of tumor. Thus far, no unexpected toxicities have been seen in the trial that would prevent the Company from continuing to study talabostat in combination with gemcitabine.

The Phase 2 study is a single-arm, two-stage study in up to 60 evaluable patients with metastatic pancreatic cancer. The primary clinical endpoint is six-month survival. Secondary study endpoints include overall survival, progression-free survival, quality of life, and performance status. The Phase 2 study protocol called for an interim assessment before advancing the study to completion. Based on the preliminary six-month survival results and the responses seen to date, the Company has decided to advance the study to completion. Final results from the study are expected mid-year 2007.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News